Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-label, Dose-escalation Study of Oral Azacitidine (CC-486) in Japanese Subjects With Hematological Neoplasms

NCT01908387 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT01908387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01908387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-label, Dose-escalation Study of Oral Azacitidine (CC-486) in Japanese Subjects With Hematological Neoplasms
Lead sponsor
Celgene Corporation
Phase
Phase 1
Overall status
Terminated
Start date
July 31, 2013
Completion date
July 31, 2015
Enrollment
2 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, chronic myelomonocytic leukemia, hodgkin lymphoma, multiple myeloma, myelodysplastic syndromes, non-hodgkin lymphoma